{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:47:35Z","timestamp":1793850455200,"version":"4.6.1"},"reference-count":86,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.rpth.2025.103286","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T17:07:38Z","timestamp":1765300058000},"page":"103286","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Can drug-induced platelet dysfunction be reversed?"],"prefix":"10.1016","volume":"10","author":[{"given":"Suzanne","family":"Maynard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander P.","family":"Bye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1951-5616","authenticated-orcid":false,"given":"Michael J.R.","family":"Desborough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2025.103286_bib1","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1111\/jth.12976","article-title":"Platelets and their microparticles as key players in pathophysiological responses","volume":"13","author":"Varon","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103286_bib2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00228-021-03250-6","article-title":"Trends in the use of oral anticoagulants, antiplatelets and statins in four European countries: a population-based study","volume":"78","author":"Garc\u00eda Rodr\u00edguez","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.rpth.2025.103286_bib3","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bjh.14520","article-title":"The aspirin story - from willow to wonder drug","volume":"177","author":"Desborough","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2025.103286_bib4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1474-4422(07)70107-2","article-title":"Change in incidence and aetiology of intracerebral haemorrhage in Oxfordshire, UK, between 1981 and 2006: a population-based study","volume":"6","author":"Lovelock","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.rpth.2025.103286_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpg.2019.04.003","article-title":"Changing epidemiology and etiology of upper and lower gastrointestinal bleeding","volume":"42-43","author":"Oakland","year":"2019","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.rpth.2025.103286_bib6","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.cgh.2018.05.061","article-title":"Incidence of upper and lower gastrointestinal bleeding in new users of low-dose aspirin","volume":"17","author":"Cea Soriano","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.rpth.2025.103286_bib7","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.117.005795","article-title":"Impact of clopidogrel therapy on mortality and cancer in patients with cardiovascular and cerebrovascular disease","volume":"11","author":"Elmariah","year":"2018","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.rpth.2025.103286_bib8","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(21)00252-0","article-title":"Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"20","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.rpth.2025.103286_bib9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000506396","article-title":"Global, regional and country-specific burden of ischaemic stroke, intracerebral haemorrhage and subarachnoid haemorrhage: a systematic analysis of the global burden of disease study 2017","volume":"54","author":"Krishnamurthi","year":"2020","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.rpth.2025.103286_bib10","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S1474-4422(18)30253-9","article-title":"Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data","volume":"17","author":"Al-Shahi Salman","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.rpth.2025.103286_bib11","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/S0140-6736(18)31033-X","article-title":"Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial","volume":"391","author":"Sprigg","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2025.103286_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019130","article-title":"Outcomes in antiplatelet-associated intracerebral hemorrhage in the TICH-2 randomized controlled trial","volume":"10","author":"Law","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.rpth.2025.103286_bib13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1474-4422(22)00338-6","article-title":"Intracerebral haemorrhage expansion: definitions, predictors, and prevention","volume":"22","author":"Morotti","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.rpth.2025.103286_bib14","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/23969873211061975","article-title":"Intracerebral haemorrhage volume, haematoma expansion and 3-month outcomes in patients on antiplatelets. a systematic review and meta-analysis","volume":"6","author":"Goeldlin","year":"2021","journal-title":"Eur Stroke J"},{"key":"10.1016\/j.rpth.2025.103286_bib15","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2025.103286_bib16","first-page":"S3","article-title":"Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations","volume":"60","author":"Kauvar","year":"2006","journal-title":"J Trauma"},{"key":"10.1016\/j.rpth.2025.103286_bib17","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00068-024-02493-z","article-title":"Higher risk of traumatic intracranial hemorrhage with antiplatelet therapy compared to oral anticoagulation-a single-center experience","volume":"50","author":"Niklasson","year":"2024","journal-title":"Eur J Trauma Emerg Surg"},{"key":"10.1016\/j.rpth.2025.103286_bib18","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.amjsurg.2016.09.036","article-title":"The effect anticoagulation status on geriatric fall trauma patients","volume":"212","author":"Coleman","year":"2016","journal-title":"Am J Surg"},{"key":"10.1016\/j.rpth.2025.103286_bib19","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/gut.2010.228437","article-title":"Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit","volume":"60","author":"Hearnshaw","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.rpth.2025.103286_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160046","article-title":"Bleeding risk with long-term low-dose aspirin: a systematic review of observational studies","volume":"11","author":"Garc\u00eda Rodr\u00edguez","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.rpth.2025.103286_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-152-1-201001050-00179","article-title":"Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial","volume":"152","author":"Sung","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rpth.2025.103286_bib22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/flgastro-2019-101395","article-title":"British Society of Gastroenterology (BSG)-led multisociety consensus care bundle for the early clinical management of acute upper gastrointestinal bleeding","volume":"11","author":"Siau","year":"2020","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.rpth.2025.103286_bib23","first-page":"654","article-title":"Acute lower GI bleeding in the UK: patient characteristics, interventions and outcomes in the first nationwide audit","volume":"67","author":"Oakland","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.rpth.2025.103286_bib24","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.cgh.2017.12.032","article-title":"Rebleeding and mortality after lower gastrointestinal bleeding in patients taking antiplatelets or anticoagulants","volume":"17","author":"Oakland","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.rpth.2025.103286_bib25","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/gutjnl-2018-317807","article-title":"Diagnosis and management of acute lower gastrointestinal bleeding: guidelines from the British Society of Gastroenterology","volume":"68","author":"Oakland","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.rpth.2025.103286_bib26","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia","volume":"377","author":"Rolnik","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103286_bib27","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.blre.2017.07.006","article-title":"Diagnosis and management of the antiphospholipid syndrome","volume":"31","author":"Chaturvedi","year":"2017","journal-title":"Blood Rev"},{"key":"10.1016\/j.rpth.2025.103286_bib28","first-page":"CD004659","article-title":"Antiplatelet agents for preventing pre-eclampsia and its complications","volume":"2019","author":"Duley","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rpth.2025.103286_bib29","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1056\/NEJMoa1401105","article-title":"Aspirin in patients undergoing noncardiac surgery","volume":"370","author":"Devereaux","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103286_bib30","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1016\/j.jacc.2024.08.024","article-title":"Aspirin monotherapy vs no antiplatelet therapy in stable patients with coronary stents undergoing low-to-intermediate risk noncardiac surgery","volume":"84","author":"Kang","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2025.103286_bib31","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1172\/JCI103356","article-title":"Determination of the life span of human blood platelets using labelled diisopropylfluorophosphonate","volume":"35","author":"Cohen","year":"1956","journal-title":"J Clin Invest"},{"key":"10.1016\/j.rpth.2025.103286_bib32","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nsb0895-637","article-title":"The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase","volume":"2","author":"Loll","year":"1995","journal-title":"Nat Struct Biol"},{"key":"10.1016\/j.rpth.2025.103286_bib33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1161\/ATVBAHA.107.150474","article-title":"Cell adhesion mechanisms in platelets","volume":"28","author":"Varga-Szabo","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.rpth.2025.103286_bib34","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1538-7836.2009.03455.x","article-title":"Calcium signaling in platelets","volume":"7","author":"Varga-Szabo","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103286_bib35","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/s-0035-1564835","article-title":"Platelet physiology","volume":"42","author":"Gremmel","year":"2016","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2025.103286_bib36","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1172\/JCI77993","article-title":"RASA3 is a critical inhibitor of RAP1-dependent platelet activation","volume":"125","author":"Stefanini","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.rpth.2025.103286_bib37","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1021\/jm800180e","article-title":"Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity","volume":"51","author":"Chackalamannil","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.rpth.2025.103286_bib38","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1161\/01.RES.0000251742.71301.16","article-title":"Activation of platelet function through G protein-coupled receptors","volume":"99","author":"Offermanns","year":"2006","journal-title":"Circ Res"},{"key":"10.1016\/j.rpth.2025.103286_bib39","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ejphar.2015.05.046","article-title":"In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist","volume":"762","author":"Hawes","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.rpth.2025.103286_bib40","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/jth.14225","article-title":"Acquired platelet antagonism: off-target antiplatelet effects of malignancy treatment with tyrosine kinase inhibitors","volume":"16","author":"Tullemans","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103286_bib41","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2014-06-583294","article-title":"Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions","volume":"124","author":"Levade","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103286_bib42","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1182\/bloodadvances.2017011999","article-title":"Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib","volume":"1","author":"Bye","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.103286_bib43","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/jth.12792","article-title":"Subcommittee on Platelet Physiology of the International Society on Thrombosis and Hemostasis. Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH","volume":"13","author":"Gresele","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103286_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102539","article-title":"How to undertake procedures while on antiplatelet agents: a hematologist's view","volume":"8","author":"Swan","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103286_bib45","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1016\/j.chest.2022.07.025","article-title":"Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline","volume":"162","author":"Douketis","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.rpth.2025.103286_bib46","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1182\/blood.2022016558","article-title":"How I use platelet transfusions","volume":"140","author":"Stanworth","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103286_bib47","doi-asserted-by":"crossref","first-page":"e756","DOI":"10.1016\/S2352-3026(20)30186-1","article-title":"Effects of the COVID-19 pandemic on supply and use of blood for transfusion","volume":"7","author":"Stanworth","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2025.103286_bib48","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1538-7836.2012.04641.x","article-title":"Reversal of the anti-platelet effects of aspirin and clopidogrel","volume":"10","author":"Li","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103286_bib49","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1538-7836.2006.02245.x","article-title":"Normalization of platelet reactivity in clopidogrel-treated subjects","volume":"5","author":"Vilahur","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103286_bib50","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejphar.2015.03.073","article-title":"Platelet transfusion reverses bleeding evoked by triple anti-platelet therapy including vorapaxar, a novel platelet thrombin receptor antagonist","volume":"758","author":"Cai","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.rpth.2025.103286_bib51","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/bjh.14344","article-title":"British Committee of Standards for Haematology. Peri-operative management of anticoagulation and antiplatelet therapy","volume":"175","author":"Keeling","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2025.103286_bib52","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/bjh.12107","article-title":"British Committee for Standards in Haematology. Guideline on the management of bleeding in patients on antithrombotic agents","volume":"160","author":"Makris","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2025.103286_bib53","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/S0140-6736(16)30392-0","article-title":"Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial","volume":"387","author":"Baharoglu","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2025.103286_bib54","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(20)30364-1","article-title":"Neuroinflammation in intracerebral haemorrhage: immunotherapies with potential for translation","volume":"19","author":"Xue","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.rpth.2025.103286_bib55","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.2019003298","article-title":"PATCH trial: explanatory analyses","volume":"135","author":"Baharoglu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103286_bib56","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jama.2025.7529","article-title":"Platelet transfusion: 2025 AABB and ICTMG international clinical practice guidelines","volume":"334","author":"Metcalf","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.rpth.2025.103286_bib57","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/jth.13962","article-title":"Preoperative platelet transfusions to reverse antiplatelet therapy for urgent non-cardiac surgery: an observational cohort study","volume":"16","author":"Baschin","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103286_bib58","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1538-7836.2012.04699.x","article-title":"Platelet transfusion for reversal of dual antiplatelet therapy in patients requiring urgent surgery: a pilot study","volume":"10","author":"Thiele","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103286_bib59","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2302\/kjm.13.177","article-title":"An active stereo-isomer (trans-form) of amcha and its antifibrinolytic (antiplasminic) action in vitro and in vivo","volume":"13","author":"Okamoto","year":"1964","journal-title":"Keio J Med"},{"key":"10.1016\/j.rpth.2025.103286_bib60","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/jth.14338","article-title":"Increased urokinase and consumption of \u03b1(2) -antiplasmin as an explanation for the loss of benefit of tranexamic acid after treatment delay","volume":"17","author":"Longstaff","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103286_bib61","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(20)30848-5","article-title":"Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2025.103286_bib62","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S0140-6736(24)01749-5","article-title":"The effect of tranexamic acid on postpartum bleeding in women with moderate and severe anaemia (WOMAN-2): an international, randomised, double-blind, placebo-controlled trial","volume":"404","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2025.103286_bib63","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1606424","article-title":"Tranexamic acid in patients undergoing coronary-artery surgery","volume":"376","author":"Myles","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103286_bib64","article-title":"Wider use of tranexamic acid to reduce surgical bleeding could benefit patients and health systems","volume":"385","author":"Roberts","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.rpth.2025.103286_bib65","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e3054","article-title":"Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis","volume":"344","author":"Ker","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.rpth.2025.103286_bib66","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(19)32233-0","article-title":"Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): a randomised, placebo-controlled trial","volume":"394","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2025.103286_bib67","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(10)60835-5","article-title":"Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial","volume":"376","author":"CRASH-2 trial collaborators","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2025.103286_bib68","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1135\/cccc19671250","article-title":"Amino acids and peptides. LXXI. Synthesis of 1-deamino-8-D-\u03b3-aminobutyrine-vasopressin, 1-deamino-8-D-lysine-vasopressin, and 1-deamino-8-D-arginine-vasopressin","volume":"32","author":"Zaoral","year":"1967","journal-title":"Collect Czech Chem Commun"},{"key":"10.1016\/j.rpth.2025.103286_bib69","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0140-6736(77)91197-7","article-title":"1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases","volume":"1","author":"Mannucci","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2025.103286_bib70","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1182\/blood-2013-04-497123","article-title":"The effect of desmopressin on platelet function: a selective enhancement of procoagulant COAT platelets in patients with primary platelet function defects","volume":"123","author":"Colucci","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103286_bib71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2025.103286_bib72","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/bloodadvances.2020003264","article-title":"ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease","volume":"5","author":"Connell","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.103286_bib73","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/bjh.14423","article-title":"Guidelines for the use of platelet transfusions","volume":"176","author":"Estcourt","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2025.103286_bib74","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/MBC.0000000000001045","article-title":"Management of surgery, menorrhagia and child-birth for patients with unclassified bleeding disorders: a systematic review of cohort studies","volume":"32","author":"Desborough","year":"2021","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.rpth.2025.103286_bib75","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1046\/j.1365-2141.2002.03460.x","article-title":"Effects of desmopressin on thrombogenesis in aspirin-induced platelet dysfunction","volume":"117","author":"Peter","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2025.103286_bib76","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1292\/jvms.65.83","article-title":"Effects of DDAVP administrated subcutaneously in dogs with aspirin-induced platelet dysfunction and hemostatic impairment due to chronic liver diseases","volume":"65","author":"Sakai","year":"2003","journal-title":"J Vet Med Sci"},{"key":"10.1016\/j.rpth.2025.103286_bib77","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s13181-012-0275-6","article-title":"Reversal of thienopyridine-induced platelet dysfunction following desmopressin administration","volume":"9","author":"Levine","year":"2013","journal-title":"J Med Toxicol"},{"key":"10.1016\/j.rpth.2025.103286_bib78","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/EJA.0000000000000775","article-title":"Evaluation of recombinant factor VIIa, tranexamic acid and desmopressin to reduce prasugrel-related bleeding: a randomised, placebo-controlled study in a rabbit model","volume":"35","author":"Bonhomme","year":"2018","journal-title":"Eur J Anaesthesiol"},{"key":"10.1016\/j.rpth.2025.103286_bib79","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/jth.13576","article-title":"Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Desborough","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103286_bib80","first-page":"Cd001884","article-title":"Desmopressin use for minimising perioperative blood transfusion","volume":"7","author":"Desborough","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rpth.2025.103286_bib81","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1474-4422(25)00160-7","article-title":"Effects of blood pressure lowering in relation to time in acute intracerebral haemorrhage: a pooled analysis of the four INTERACT trials","volume":"24","author":"Wang","year":"2025","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.rpth.2025.103286_bib82","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1161\/STROKEAHA.114.006061","article-title":"Desmopressin improves platelet activity in acute intracerebral hemorrhage","volume":"45","author":"Naidech","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.rpth.2025.103286_bib83","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1474-4422(23)00157-6","article-title":"Desmopressin for patients with spontaneous intracerebral haemorrhage taking antiplatelet drugs (DASH): a UK-based, phase 2, randomised, placebo-controlled, multicentre feasibility trial","volume":"22","author":"Desborough","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.rpth.2025.103286_bib84","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1755-5922.2009.00096.x","article-title":"Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist","volume":"27","author":"Husted","year":"2009","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.rpth.2025.103286_bib85","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40262-023-01245-3","article-title":"Clinical and pre-clinical pharmacokinetics and pharmacodynamics of bentracimab","volume":"62","author":"Ortega-Paz","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rpth.2025.103286_bib86","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100047","article-title":"Bentracimab for ticagrelor reversal in patients undergoing urgent surgery","volume":"1","author":"Bhatt","year":"2022","journal-title":"NEJM Evid"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925006107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925006107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:53:45Z","timestamp":1778896425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037925006107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2475037925006107"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103286","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can drug-induced platelet dysfunction be reversed?","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103286","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"103286"}}